Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson’s disease
Open accessAbstract
BACKGROUND: Deposition of α-synuclein and neuroinflammation are key pathological features of Parkinson's disease (PD). There is no cure for the disease; however, targeting the pathological features might be available to modulate the disease onset and progression. Hypoestoxide (HE) has been demonstrated as a NF-κB modulator, thereby acting as a potential anti-inflammatory and anti-cancer drug. METHODS: In order to assess the effect of HE in a mouse model of PD, mThy1-α-syn transgenic mice received intraperitoneal (IP) injections of either vehicle or HE (5 mg/kg) daily for 4 weeks. RESULTS: Treatment of HE decreased microgliosis, astrogliosis, and pro-inflammatory cytokine gene expression in α-syn transgenic mice. HE administration also prevented the loss of dopaminergic neurons and ameliorated motor behavioral deficits in the α-syn transgenic mice, and α-synuclein pathology was significantly reduced by treatment of HE. In addition, increased levels of nuclear phosphorylated NF-κB in the frontal cortex of α-syn transgenic mice were significantly reduced by HE administration. CONCLUSIONS: These results support the therapeutic potential of HE for PD and other α-synuclein-related diseases.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Treating synucleinopathy animal models with drugs to reduce neuroinflammation decreases α-synuclein neuropathology.
“but when these animals were treated with drugs to reduce neuroinflammation, α-synuclein neuropathology also decreased (57, 58).”
From LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies (2020) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Spencer, B. J., Emadi, S., Desplats, P., Eleuteri, S., Michael, S. A., Kosberg, K. A., Shen, J., Rockenstein, E. M., Patrick, C., Adame, A., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.129 · Cited by 84 · see citing works
Self-citationRetractedPolazzi, E., Mengoni, I., Caprini, M., Peña‐Altamira, E., Kurtys, E., & Monti, B. (2012) · Neurosignals · doi:10.1159/000337115 · Cited by 9,023 · see citing works
Microglia: Active sensor and versatile effector cells in the normal and pathologic brain
Hanisch, U.-K., & Kettenmann, H. (2007) · Nature Neuroscience · doi:10.1038/nn1997 · Cited by 3,676 · see citing works
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984 · see citing works
Neuropathology of Parkinson's Disease
Forno, L. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199603000-00001 · Cited by 1,556 · see citing works
Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265 · see citing works
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183 · see citing works
Lee, H.-J., Suk, J.-E., Patrick, C., Bae, E.-J., Cho, J.-H., Rho, S., Hwang, D., Masliah, E., & Lee, S.-J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081125 · Cited by 877 · see citing works
Self-citationKim, C., Ho, D.-H., Suk, J.-E., You, S., Michael, S., Kang, J., Joong Lee, S., Masliah, E., Hwang, D., Lee, H.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms2534 · Cited by 856 · see citing works
Self-citationIntravesicular Localization and Exocytosis of α-Synuclein and its Aggregates
Lee, H.-J., Patel, S. S., & Lee, S. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0692-05.2005 · Cited by 798 · see citing works
Rockenstein, E., Mallory, M., Hashimoto, M., Song, D., Shults, C. W., Lang, I., & Masliah, E. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10231 · Cited by 502 · see citing works
Self-citationT helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis.
Harris, J., Haro, S. A. D., Master, S. S., Keane, J., Roberts, E. A., Delgado, M. A., & Deretic, V. (2007) · Immunity · doi:10.1016/j.immuni.2007.07.022 · Cited by 497 · see citing works
Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human α-Synuclein
Fleming, S. M., Salcedo, J. D., Fernagut, P., Rockenstein, E. M., Masliah, E., Levine, M. S., & Chesselet, M. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.3080-04.2004 · Cited by 477 · see citing works
Self-citationSynuclein activates microglia in a model of Parkinson's disease
Su, X., Maguire-Zeiss, K. A., Giuliano, R., Prifti, L., Venkatesh, K., & Federoff, H. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.006 · Cited by 474 · cited 1× · see citing works
“Previous studies have shown that exposure to various forms of recombinant α-synuclein induces microglia activation [25, 33–35].”
BackgroundMicroglia: actively surveying and shaping neuronal circuit structure and function
Wake, H., Moorhouse, A. J., Miyamoto, A., & Nabekura, J. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.007 · Cited by 448 · see citing works
Neuroinflammatory processes in Parkinson's disease
Hunot, S., & Hirsch, É. C. (2003) · Annals of Neurology · doi:10.1002/ana.10481 · Cited by 399 · see citing works
Harris, J. (2011) · Cytokine · doi:10.1016/j.cyto.2011.08.022 · Cited by 392 · see citing works
Gao, H.-M., Zhang, F., Zhou, H., Kam, W., Wilson, B., & Hong, J.-S. (2011) · Environmental Health Perspectives · doi:10.1289/ehp.1003013 · Cited by 355 · cited 1× · see citing works
“Furthermore, inhibition of neuroinflammatory enzymes, such as NADPH oxidase and iNOS decreased nigral α-synuclein deposition in αsyn-tg mice [15] once again suggesting that blocking or preventing inflammation may prevent PD pathology.”
BackgroundGames, D., Valera, E., Spencer, B. J., Rockenstein, E. M., Mante, M., Adame, A., Patrick, C., Ubhi, K. K., Nuber, S., Sacayon, P., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.5314-13.2014 · Cited by 322 · see citing works
Self-citationNeuroinflammatory processes in Parkinson's disease
Hirsch, É. C., Hunot, S., & Hartmann, A. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.10.013 · Cited by 298 · see citing works
The influence of microglia on the pathogenesis of Parkinson's disease
Long-Smith, C. M., Sullivan, A. M., & Nolan, Y. M. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.08.001 · Cited by 296 · see citing works
Jang, A., Lee, H., Suk, J., Jung, J., Kim, K., & Lee, S. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06695.x · Cited by 281 · see citing works
Nitrated alpha‐synuclein‐activated microglial profiling for Parkinson’s disease
Reynolds, A. D., Glanzer, J. G., Kadiu, I., Ricardo-Dukelow, M., Chaudhuri, A., Ciborowski, P. S., Cerny, R. L., Gelman, B. B., Thomas, M. P., Mosley, R. L., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05087.x · Cited by 244 · see citing works
Autophagic failure promotes the exocytosis and intercellular transfer of α-synuclein
Lee, H.-J., Cho, E.-D., Lee, K., Kim, J., Cho, S., & Lee, S. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.45 · Cited by 199 · see citing works
Kahn, M. S., Kranjac, D., Alonzo, C. A., Haase, J. H., Cedillos, R. O., McLinden, K. A., Boehm, G. W., & Chumley, M. J. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.01.010 · Cited by 177 · see citing works
The relation between α-synuclein and microglia in Parkinson’s disease: Recent developments
Sánchez-Guajardo, V., Tentillier, N., & Romero‐Ramos, M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.02.008 · Cited by 171 · see citing works
Park, J., Paik, S. R., Jou, I., & Park, S. M. (2008) · Glia · doi:10.1002/glia.20691 · Cited by 151 · see citing works
Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers
Lee, H.-J., Baek, S. M., Ho, D. H., Suk, J., Cho, E.-D., & Lee, S. (2011) · Experimental & Molecular Medicine · doi:10.3858/emm.2011.43.4.026 · Cited by 137 · see citing works
Park, H.-J., Lee, S. J., Kim, S. H., Han, J., Bae, J., Kim, S. J., Park, C., & Chun, T. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.10.020 · Cited by 135 · see citing works
Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy
Kim, C., Rockenstein, E., Spencer, B., Kim, H.-K., Adame, A., Trejo, M., Stafa, K., Lee, H.-J., Lee, S.-J., & Masliah, E. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.044 · Cited by 135 · see citing works
Self-citationIfuku, M., Katafuchi, T., Mawatari, S., Noda, M., Miake, K., Sugiyama, M., & Fujino, T. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-197 · Cited by 130 · see citing works
HIV-1 Inhibits Autophagy in Bystander Macrophage/Monocytic Cells through Src-Akt and STAT3
Grol, J. V., Subauste, M. C., Andrade, R. M., Fujinaga, K., Nelson, J. A. E., & Subauste, C. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011733 · Cited by 130 · see citing works
Bae, E.-J., Ho, D. H., Park, E., Jung, J. W., Cho, K., Hong, J. H., Lee, H.-J., Kim, K. P., & Lee, S. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4429 · Cited by 126 · see citing works
Kongsui, R., Beynon, S. B., Johnson, S. J., & Walker, F. R. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0182-7 · Cited by 115 · see citing works
Autophagy in the immune response to tuberculosis: clinical perspectives
Cheallaigh, C. N., Keane, J., Lavelle, E., Hope, J., & Harris, J. (2011) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04381.x · Cited by 110 · see citing works
Controlling the mass action of α‐synuclein in Parkinson’s disease
Kim, C., & Lee, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05612.x · Cited by 105 · see citing works
Self-citationEndotoxin induces a delayed loss of TH-IR neurons in substantia nigra and motor behavioral deficits
Liu, Y., Qin, L., Wilson, B., Wu, X., Qian, L., Granholm, A.-C., Crews, F. T., & Hong, J.-S. (2008) · NeuroToxicology · doi:10.1016/j.neuro.2008.02.014 · Cited by 84 · see citing works
Rockenstein, E. M., Crews, L. A., & Masliah, E. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.013 · Cited by 80 · see citing works
Self-citationValera, E., Mante, M., Anderson, S., Rockenstein, E. M., & Masliah, E. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0320-x · Cited by 66 · see citing works
Self-citationβ1-integrin-dependent migration of microglia in response to neuron-released α-synuclein
Kim, C., Cho, E.-D., Kim, H.-K., You, S., Lee, H.-J., Hwang, D., & Lee, S. (2014) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.6 · Cited by 60 · see citing works
Self-citationHypoestoxide, a Novel Anti-inflammatory Natural Diterpene, Inhibits the Activity of IκB Kinase
Ojo-Amaize, E. A., Kapahi, P., Kakkanaiah, V. N., Takahashi, T., Shalom‐Barak, T., Cottam, H. B., Adesomoju, A. A., Nchekwube, E. J., Oyemade, O. A., Karin, M., et al. (2001) · Cellular Immunology · doi:10.1006/cimm.2001.1798 · Cited by 48 · see citing works
Self-citationOjo-Amaize, E. A., Nchekwube, E. J., Cottam, H. B., Bai, R., Verdier‐Pinard, P., Kakkanaiah, V. N., Varner, J. A., Leoni, L. M., Okogun, J. I., Adesomoju, A. A., et al. (2002) · PubMed · Cited by 26 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Wong, Y. C., & Krainc, D. (2017) · Nature Medicine · doi:10.1038/nm.4269 · Cited by 897 · see citing works
Shaping the Nrf2-ARE-related pathways in Alzheimer’s and Parkinson’s diseases
Fão, L., Mota, S. I., & Rego, A. C. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100942 · Cited by 270 · see citing works
Animal models of α-synucleinopathy for Parkinson disease drug development
Koprich, J. B., Kalia, L. V., & Brotchie, J. M. (2017) · Nature reviews. Neuroscience · doi:10.1038/nrn.2017.75 · Cited by 235 · see citing works
Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson’s Disease
Li, Y., Xia, Y., Yin, S., Wan, F., Hu, J., Kou, L., Sun, Y., Wu, J., Zhou, Q., Huang, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.719807 · Cited by 230 · see citing works
Kim, C., Spencer, B., Rockenstein, E., Yamakado, H., Mante, M., Adame, A., Fields, J. A., Masliah, D., Iba, M., Lee, H.-J., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0276-2 · Cited by 157 · see citing works
Self-citationTronel, C., Largeau, B., Ribeiro, M. J., Guilloteau, D., Dupont, A.-C., & Arlicot, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040802 · Cited by 154 · see citing works
RETRACTED ARTICLE: LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation
Bae, E.-J., Kim, D.-K., Kim, C., Mante, M., Adame, A., Rockenstein, E., Ulusoy, A., Klinkenberg, M., Jeong, G. R., Bae, J. R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05958-z · Cited by 149 · see citing works
Self-citationRetractedExposure to bacterial endotoxin generates a distinct strain of α-synuclein fibril
Kim, C., Lv, G., Lee, J. S., Jung, B. C., Masuda-Suzukake, M., Hong, C.-S., Valera, E., Lee, H.-J., Paik, S. R., Hasegawa, M., et al. (2016) · Scientific Reports · doi:10.1038/srep30891 · Cited by 138 · see citing works
Self-citationIba, M., Kim, C., Sallin, M., Kwon, S., Verma, A., Overk, C., Rissman, R. A., Sen, R., Sen, J. M., & Masliah, E. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01888-0 · Cited by 120 · see citing works
Self-citationRetractedCurrent Therapies in Clinical Trials of Parkinson’s Disease: A 2021 Update
Prasad, E. M., & Hung, S. (2021) · Pharmaceuticals · doi:10.3390/ph14080717 · Cited by 112 · see citing works
Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
Menon, S. A., Armstrong, S. E. M., Hamzeh, A. M., Visanji, N. P., Sardi, S. P., & Tandon, A. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.852003 · Cited by 107 · see citing works
El‐Agnaf, O. M. A., Overk, C., Rockenstein, E. M., Mante, M., Florio, J. B., Adame, A., Vaikath, N. N., Majbour, N. K., Lee, S., Kim, C., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.05.002 · Cited by 82 · see citing works
Self-citationRetractedLRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies
Kim, C., Beilina, A., Smith, N., Li, Y., Kim, M., Kumaran, R., Kaganovich, A., Mamais, A., Adame, A., Iba, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay0399 · Cited by 79 · see citing works
Self-citationPatel, R. R., Khom, S., Steinman, M. Q., Varodayan, F. P., Kiosses, W. B., Hedges, D. M., Vlkolinský, R., Nadav, T., Polis, I. Y., Bajo, M., et al. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.10.009 · Cited by 70 · see citing works
Gureev, A. P., Sadovnikova, I. S., Starkov, N. N., Starkov, A. A., & Popov, V. N. (2020) · Brain Sciences · doi:10.3390/brainsci10110847 · Cited by 61 · see citing works
Varodayan, F. P., Pahng, A. R., Davis, T. D., Gandhi, P., Bajo, M., Steinman, M. Q., Kiosses, W. B., Blednov, Y. A., Burkart, M. D., Edwards, S., et al. (2023) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2023.02.020 · Cited by 50 · see citing works
Alpha-Synuclein and Microglia in Parkinson’s Disease: From Pathogenesis to Therapeutic Prospects
Eo, H., Kim, S., Jung, U. J., & Kim, S. R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237243 · Cited by 47 · see citing works
MicroRNA-216a inhibits neuronal apoptosis in a cellular Parkinson’s disease model by targeting Bax
Yang, X., Zhang, M., Wei, M., Wang, A., Deng, Y., & Cao, H. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00546-x · Cited by 46 · see citing works
Welcome, M. O. (2020) · PharmaNutrition · doi:10.1016/j.phanu.2020.100176 · Cited by 41 · see citing works
Genetic Imaging of Neuroinflammation in Parkinson’s Disease: Recent Advancements
Yao, L., Wu, J., Koç, S., & Lu, G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.655819 · Cited by 41 · see citing works
Kim, C., Kwon, S., Iba, M., Spencer, B. J., Rockenstein, E. M., Mante, M., Adame, A., Shin, S. J., Fields, J. A., Rissman, R. A., et al. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00562-6 · Cited by 39 · see citing works
Self-citationRetractedKhor, S. L. Q., Ng, K. Y., Koh, R. Y., & Chye, S. M. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230330093829 · Cited by 35 · see citing works
Tajiri, N., Hernandez, D., Acosta, S., Shinozuka, K., Ishikawa, H., Ehrhart, J. C., Diamandis, T., Gonzales-Portillo, C., Borlongan, M. C., Tan, J., et al. (2014) · Brain Research · doi:10.1016/j.brainres.2014.02.041 · Cited by 22 · see citing works
Roshanbin, S., Aniszewska, A., Gumucio, A., Masliah, E., Erlandsson, A., Bergström, J. J. E., Ingelsson, M., & Ekmark‐Lewén, S. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.01.010 · Cited by 21 · see citing works
Self-citationMechanisms of Autoimmune Cell in DA Neuron Apoptosis of Parkinson’s Disease: Recent Advancement
Zheng, Z., Zhang, S., Zhang, H., Gao, Z., Wang, X., Liu, X., Cheng, X., Yao, L., & Lu, G. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/7965433 · Cited by 20 · see citing works
Synaptic vesicle-omics in mice captures signatures of aging and synucleinopathy
Gao, V., Chlebowicz, J., Gaskin, K., Briano, J. A., Komer, L. E., Pineda, A., Jhalani, S., Ahmad, S., Uwaifo, E., Black, L. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59441-7 · Cited by 17 · see citing works
Recalibrating the Why and Whom of Animal Models in Parkinson Disease: A Clinician’s Perspective
Sturchio, A., Rocha, E. M., Kauffman, M. A., Marsili, L., Mahajan, A., Saraf, A., Vizcarra, J. A., Guo, Z., & Espay, A. J. (2024) · Brain Sciences · doi:10.3390/brainsci14020151 · Cited by 18 · see citing works
α -Synuclein Trafficking in Parkinson’s Disease: Insights From Fly and Mouse Models
Cheng, J., Lu, Q., Li, S., & Ho, M. S.-C. (2018) · ASN NEURO · doi:10.1177/1759091418812587 · Cited by 14 · see citing works
What Can Inflammation Tell Us about Therapeutic Strategies for Parkinson’s Disease?
Xue, J., Tao, K., Wang, W., & Wang, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031641 · Cited by 14 · see citing works
Targeting NLRP3 Inflammasomes: A Trojan Horse Strategy for Intervention in Neurological Disorders
Tork, M. A. B., Fotouhi, S., Roozi, P., & Negah, S. S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04359-2 · Cited by 9 · see citing works
Siddu, A., David, L. S., Lauinger, N. D., Chen, X., Saint‐Pierre, M., Alpaugh, M., Durcan, T. M., & Cicchetti, F. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105042 · Cited by 9 · see citing works
Chatila, Z. K., Yadav, A., Mares, J., Flowers, X. E., Yun, T., Rashid, M., Talcoff, R., Pelly, Z., Zhang, Y., Jager, P. L. D., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.17.540842 · Cited by 11 · see citing works
Emeribe, A. U., Anyanwu, S. O., Isong, I. K., Bassey, U. R., Inyang, I. J., Ibeneme, E., Asemota, E. A., Okhormhe, Z., Icha, B. E., & Abdullahi, I. N. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.07.045 · Cited by 8 · see citing works
Drug discovery and development for Parkinson’s disease: are preclinical models good enough?
Reinares-Sebastián, A., Esteban-García, N., Takada, M., & Trigo‐Damas, I. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1692592 · Cited by 5 · see citing works
Labdane-type diterpenoids from Hypoestes phyllostachya inhibit pancreatic cancer stem cells
Yan, T., Ding, L., Chen, Y., Hu, G.-X., Qu, L., Hu, M., Ma, Y., Yuan, R., Jia, L., Zhao, M.-J., et al. (2025) · Phytochemistry · doi:10.1016/j.phytochem.2025.114650 · Cited by 2 · see citing works
Role of Microglia in Parkinson’s Disease Pathology
Ciolac, D., & González‐Escamilla, G. (2024) · Neuromethods · doi:10.1007/978-1-0716-4083-8_4 · Cited by 1 · see citing works
McGregor, B. A., Raihan, M. O., Brishti, A., Hur, J., & Porter, J. E. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1544971 · Cited by 1 · see citing works
Egbe, A., Eyo, A.-A. O., Joseph, I. I., & Michael, A. A. (2022) · The Journal of Phytopharmacology · doi:10.31254/phyto.2022.11507
Why Hypoestoxide is the Ideal Candidate Drug for Disease Modifying Treatment of Parkinson’s Disease
Ojo-Amaize, E. A., & Cottam, H. B. (2023) · Neurology - Research & Surgery · doi:10.33425/2641-4333.1050
Self-citationKim, J. (2025) · International journal of high school research · doi:10.36838/v7i4.11
Fertan, E., Danial, J. S. H., Neame, S. J., Lam, J. Y. L., Cotton, M. W., Burke, M., Xia, Z., Wu, Y., Powney, B., Imaizumi, Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.16.676632
Fertan, E., Danial, J. S. H., Neame, S. J., Lam, J. Y. L., Cotton, M. W., Burke, M., Xia, Z., Wu, Y., Powney, B., Imaizumi, Y., et al. (2026) · Cell Reports Methods · doi:10.1016/j.crmeth.2026.101418
Yuan, L., Asghar, M. A., Zhang, Y., Yang, Y., Zhang, X., & Zhao, Q. (2026) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70909
Propagation of α-synuclein pathology: models, mechanisms and future goals
Zolin, A., Weber, S. A., Xie, Y. X., & Burré, J. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00038-9
Paasch, D., Haake, K., Kan, C., Ulpiano, C., Nikolouli, E., Jang, M.-S., Klassen, M.-C., Epstein, M., Sugimura, R., & Lachmann, N. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02907-x
- Authors
- Kim, C., Ojo-Amaize, E., Spencer, B., Rockenstein, E., Mante, M., Desplats, P., Wrasidlo, W., Adame, A., Nchekwube, E., Oyemade, O., Okogun, J., Chan, M., Cottam, H., & Masliah, E.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Masliah, Eliezer
- ORCID
- Venue
- Journal of Neuroinflammation
- Published
- 2015-12
- Volume
- 12
- Issue
- 1
- Pages
- 236-236
- ISSN
- 1742-2094 (ISSN-L)
- PMC
- PMC4683943
- OpenAlex
- W2204454339
- Cited by
- 45
- References
- 42
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 6 · 2020: 6 · 2019: 1 · 2018: 4 · 2017: 4 · 2016: 1 · 2014: 1
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Neuroinflammation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (AG18440, AG043384, NS057096)
- National Research Foundation of Korea (2013R1A6A3A03023385)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, alpha-synuclein, neuroinflammation, NF-κB, microglial activation, astrocyte activation, inflammatory cytokines, dopaminergic neuron loss, motor impairment, anti-inflammatory therapy
- MeSH terms
- Animals, Disease Models, Animal, Diterpenes, Female, Humans, Inflammation, Mice, Transgenic, Parkinson Disease, NF-kappa B, Neocortex, Mice, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
